Patrizia Pellegrini

Patrizia Pellegrini

Auto-generated profile, based on publicly available information

Patrizia Pellegrini

CNR Institute of Organ Transplantation and Immunocytology (ITOI), L'Aquila, Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 1996 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
PPP. Pellegrini
P. Pellegrini
ABAnna Maria Berghella
Anna Maria Berghella
TBT. Del Beato
T. Del Beato
SCSergio Cicia
Sergio Cicia
DADomenico Adorno
Domenico Adorno
CCCarlo Umberto Casciani
Carlo Umberto Casciani

1 October 2003 in Transplant Immunology
Verified
Journal Article
Closed access
PPPatrizia Pellegrini
Patrizia Pellegrini
ABAnna Maria Berghella
Anna Maria Berghella
ICIda Contasta
Ida Contasta
DADomenico Adorno
Domenico Adorno

22 December 2011 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
PPPatrizia Pellegrini
Patrizia Pellegrini
ICIda Contasta
Ida Contasta
TBTiziana Del Beato
Tiziana Del Beato
FCFabiana Ciccone
Fabiana Ciccone
ABAnna Maria Berghella
Anna Maria Berghella
Studies focusing on gender have shown that differences exist in how the immune system responds to disease and therapy. Understanding how gender influences immunological mechanisms in health and disease and identifying gender-specific biomarkers could lead to specifically tailored treatment and ultimately improve therapeutic success rates. T helper1 (Th1) and Th2 cytokines (Th1/Th2) have pivotal roles in the homeostasis of Th1 and Th2 cell network functions in the immune response but sex steroids affect Th1/Th2 production in different ways and a natural sexual dimorphism in the immune response has been shown. In order to investigate these differences further, we developed Th-cytokine data-driven models of the immune response and evaluated healthy subject peripheral blood samples. Independent cohorts of colorectal cancer and adenoma patients were also studied for comparison purposes. Our results show that the interferon (IFN)γproduction pathway for immune response homeostasis is specific to men whilst the interleukin- (IL-) 6 production pathway for immune response homeostasis is specific to women. The IL-10 pathway for restoring immune system resting homeostasis was common to both but was controlled by the respective gender-specific pathways. These gender pathways could well be used as targets and biomarkers in translational research into developing new clinical strategies.

12 January 1998 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
ABA. M. Berghella
A. M. Berghella
PPPatrizia Pellegrini
Patrizia Pellegrini
TBTiziana Del Beato
Tiziana Del Beato
MMMatteo Marini
Matteo Marini
ETEnnio Tomei
Ennio Tomei
CCCarlo Umberto Casciani
Carlo Umberto Casciani

23 September 2000 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
PPPatrizia Pellegrini
Patrizia Pellegrini
ICIda Contasta
Ida Contasta
ABAnna Maria Berghella
Anna Maria Berghella
EGEstevano Gargano
Estevano Gargano
CMCesare Mammarella
Cesare Mammarella
DADomenico Adorno
Domenico Adorno

1 June 2005 in Neuroimmunomodulation
Verified
Journal Article
Closed access
PPPatrizia Pellegrini
Patrizia Pellegrini
RTRocco Totaro
Rocco Totaro
ICIda Contasta
Ida Contasta
ABAnna Maria Berghella
Anna Maria Berghella
ACAntonio Carolei
Antonio Carolei
DADomenico Adorno
Domenico Adorno
Objectives: The immunological effect of CD30 on dendritic cells (DCs) was examined in a comparative study of patients with relapsing-remitting multiple sclerosis (RRMS). The patients were divided into two groups on the basis of interferon (IFN)β-1a treatment: IFNβ-1a-treated patients and untreated patients. We have already shown that CD30 is a marker of cells involved in the regulation of the balance between TH1 and TH2 immune responses and so the aim of this study was to confirm this role in DCs and, consequently, to clarify the immunopathological mechanisms of MS and the causes of immunosuppressive drug failure. Methods: We studied network interactions between soluble (s) CD30 and TH1/TH2 cytokines in the supernatants of CD14+-derived immature DC (IDC) and DC cultures from treated and untreated patients. Network interactions between the sCD30 and cytokines in IDC and DC supernatants were also evaluated in relation to TH1/TH2 cytokine serum levels. Results: Our overall results show that CD30 is expressed on IDCs and DCs, indicating an immunological role in resting and activated physiological conditions. This role would appear to be the regulation of the resting and activated physiological balance between the TH1/TH2 immune functions as abnormal increases in sCD30 levels result in impaired regulation. Further studies are undoubtedly required to clarify this situation. IFNβ-1a treatment was found to determine a fall in sCD30 levels, leading to the restoration of the normal functional selection of IDCs from progenitor cells and the regulation of the TH1/TH2 network balance. However, IFNβ-1a treatment may also be responsible for the in vivo suppression of CD30-mediated TH1-DC functions in immune activation. TH1-DC functions are involved in the induction of T-regulatory cells for the physiological deletion of self-aggressive cells. Conclusion: We conclude that CD30 is an important costimulatory molecule and marker of a regulatory subpopulation of DCs which induces and modulates immune cells involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. Elucidating the mechanisms restoring DC and T-regulatory cell function could lead to more effective therapy and strategies for the prevention and treatment of immunopathological conditions such as autoimmunity, transplant rejection, allergy and tumors.